Because the classification of propafenone and moricizine is not clear, we measured in 20 specifically equipped isolated rabbit hearts QRS duration, QT interval, action potential duration at 90% of repolarization (APD90), effective refractory period (ERP), conduction time (CT), and rise velocity (Rv) of the monophasic action potentials (AP) during exposure to moricizine and propafenone in comparison with procainamide. Propafenone and procainamide prolonged APD90 and JT. All drugs increased ERP. Propafenone demonstrated marked tonic sodium channel block. Onset of use-dependent kinetics (tau on), defined as change in Rv as fraction per beat at 300 ms cycle length (CL), were 0.047 +/- 0.004/beat for procainamide, 0.050 +/- 0.004/beat for propafenone, and 0.022 +/- 0.003/beat for miricizine. Recovery kinetics, defined as recovery of Rv after cessation of pacing, had a time constant of 5.3 +/- 0.7 s for procainamide, 6.3 +/- 0.8 s for propafenone, and 25.0 +/- 1.3 s for moricizine. Based on these data, moricizine must be classified as a Ic agent, whereas propafenone demonstrates pronounced tonic sodium channel block, in addition to its phasic block, which is similar to class Ia kinetics.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/00005344-199424050-00010 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: Flecainide and other class-Ic antiarrhythmic drugs (AADs) are widely used in Andersen-Tawil syndrome type 1 (ATS1) patients. However, class-Ic drugs might be proarrhythmic in some cases. We investigated the molecular mechanisms of class-I AADs proarrhythmia and whether they might increase the risk of death in ATS1 patients with structurally normal hearts.
View Article and Find Full Text PDFPropafenone facilitates mitochondrial-associated ferroptosis and synergizes with immunotherapy in melanoma.
J Immunother Cancer
November 2024
Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan Province, China
Article Synopsis
- * Researchers screened 200 FDA-approved cardiovascular drugs and identified propafenone, a heart medication, as a potential enhancer of ferroptosis in melanoma treatment.
- * Results showed that combining propafenone with ferroptosis inducers leads to significant tumor regression and improved survival rates in animal models, suggesting its potential to boost immunotherapy responses in melanoma patients.
Long-term clinical course of patients with catecholaminergic polymorphic ventricular tachycardia: A more than 10-year follow-up cohort study.
Ann Pediatr Cardiol
October 2024
Department of Pediatric Cardiology, Veltischev Research and Clinical Institute for Pediatrics and Pediatric Surgery of the Pirogov Russian National Research Medical University, Moscow, Russia.
Article Synopsis
- - The study focused on 12 children diagnosed with catecholaminergic polymorphic ventricular tachycardia (CPVT), investigating their long-term health outcomes, including how they responded to treatments and the incidence of heart-related events over a follow-up period of about 20 years.
- - Despite beta-blocker therapy, a significant number of patients continued to experience syncope and supraventricular tachycardia (SVT), indicating that the risk of cardiac events remains high, even with treatment.
- - Genetic testing revealed mutations in several patients, highlighting the importance of personalized treatment strategies, and suggesting that combining beta-blockers with antiarrhythmic medications might be beneficial for managing CPVT.
Background: This study investigated drug-drug interactions in patients with atrial fibrillation taking both a direct oral anticoagulant (DOAC) and an antiarrhythmic drug.
Methods And Results: Using data from the National Health Insurance database (2012-2018), we identified 78 805 patients with atrial fibrillation on DOACs, with 24 142 taking amiodarone, 8631 taking propafenone, 2784 taking dronedarone, 297 taking flecainide, 177 taking sotalol, and 42 772 on DOACs alone. Patients with bradycardia, heart block, heart failure, mitral stenosis, prosthetic valves, or incomplete data were excluded.
Development of new K2.1 channel openers from propafenone analogues.
Br J Pharmacol
February 2025
Department of Medical Physiology, Division Heart and Lungs, University Medical Center Utrecht, Utrecht, The Netherlands.
Article Synopsis
- Reduced functioning of the K2.1 potassium channel is linked to conditions like heart failure and Andersen-Tawil Syndrome, making it crucial to find treatments that specifically target this channel, as current therapies do not.
- Research analyzed the effects of propafenone and its analogues on the K2.1 channel using techniques like patch-clamp electrophysiology and western blot analysis, highlighting the potential of these compounds to improve potassium current.
- Notably, the analogue GPV0057 increased the potassium current without blocking it at low concentrations, suggesting it could be a viable treatment option for diseases related to K2.1 deficiency.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!